Loading...
Market
FDA approval for expanded use of BLINCYTO® in pediatric B-cell ALL by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
Amgen's BLINCYTO® Improves Survival in Pediatric B-Cell ALL: AALL1731 Results at ASH24
Dec 8, 2024, 02:04 PM
At the American Society of Hematology's (ASH) 2024 Annual Meeting (#ASH24), significant clinical trial results were presented, highlighting advancements in the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). A key study presented by the Children's Oncology Group (COG) revealed that the addition of blinatumomab, marketed as BLINCYTO® by Amgen, to induction chemotherapy significantly improved disease-free survival in children with standard-risk B-ALL. The full results of the AALL1731 trial demonstrated enhanced survival rates when blinatumomab was added to chemotherapy regimens for newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
